DOP75: Video capsule endoscopy may detect active small bowel Crohn’s disease requiring change of treatment despite unremarkable ileo-colonic anastomosisECCO’23 Copenhagen 2023
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapyECCO’23 Copenhagen 2023
DOP77: Is durable remission achievable after ileocolic resection for Crohn’s disease ? Long-term results of a prospective multicentric cohort study of the GETAID ChirurgieECCO’23 Copenhagen 2023
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scoresECCO’23 Copenhagen 2023
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapyECCO’23 Copenhagen 2023
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).ECCO’23 Copenhagen 2023
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study ResultsECCO’23 Copenhagen 2023
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s diseaseECCO’23 Copenhagen 2023
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide studyECCO’23 Copenhagen 2023
DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumabECCO’23 Copenhagen 2023
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s diseaseECCO’23 Copenhagen 2023
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximabECCO’23 Copenhagen 2023
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD studyECCO’23 Copenhagen 2023
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patientsECCO’23 Copenhagen 2023